Zobrazeno 1 - 10 of 40 pro vyhledávání: '"J A McCubrey"'
1
GSK-3β can regulate the sensitivity of pancreatic cells to chemotherapeutic drugs, targeted therapeutics and nutraceuticals
Autor: S. L. Abrams, S. M. Akula, A. K Meher, L. S. Steelman, A. Gizak, P. Duda, D. Rakus, A. M. Martelli, S. Ratti, L. Cocco, G. Montalto, M. Cervello, P. Ruvolo, M. Libra, L. Falzone, S. Candido, J. A. McCubrey.
Glycogen synthase kinase-3 (GSK-3) is a regulator of signaling pathways. KRas is frequently mutated in pancreatic cancers. The growth of certain pancreatic cancers is KRas-dependent and can be suppressed by GSK-3 inhibitors, documenting a link betwee
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4094::ff10e8f2f8eb627ea56477a5983b746a
http://hdl.handle.net/11585/855456
Zobrazit plný text záznamu
2
Targeting the phosphatidylinositol 3‐kinase/Akt/mechanistic target of rapamycin signaling pathway in B‐lineage acute lymphoblastic leukemia: An update
Autor: C. Simioni, A. M. Martelli, G. Zauli, M. Vitale, G. Gobbi, J. A. McCubrey, S. Capitani, L. M. Neri.
Publikováno v: Journal of Cellular Physiology. 233:6440-6454
Despite considerable progress in treatment protocols, B-lineage acute lymphoblastic leukemia (B-ALL) displays a poor prognosis in about 15-20% of pediatric cases and about 60% of adult patients. In addition, life-long irreversible late effects from c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f29279387fae7914fe9c0864d56f933f
https://doi.org/10.1002/jcp.26539
Zobrazit plný text záznamu
3
Therapeutic targeting of CK2 in acute and chronic leukemias
Autor: F Buontempo, J A McCubrey, E Orsini, M Ruzzene, A Cappellini, A Lonetti, C Evangelisti, F Chiarini, J T Barata, A M Martelli
Publikováno v: Leukemia
CK2 is a ubiquitously expressed, constitutively active Ser/Thr protein kinase, which is considered the most pleiotropic protein kinase in the human kinome. Such a pleiotropy explains the involvement of CK2 in many cellular events. However, its predom
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba380f10aee07e2c328c1775943602b3
https://doi.org/10.1038/leu.2017.301
Zobrazit plný text záznamu
4
Drug-resistance in FL5.12 doxorubicin-resistant hematopoietic cells: elevated MDR1 and decreased BCL2-family member expression and increased side-population positive cells
Autor: L. S. Steelman, S. L. Abrams, P. Ruvolo, V. Ruvolo, L. Cocco, S. Ratti, A. M. Martelli, L. Neri, S. Candido, M. Libra, J. A. McCubrey.
Chemotherapeutic drug treatment can result in the emergence of drug-resistant cells. By culturing an interleukin-3 (IL-3)-dependent cell line, FL5.12 cells in the presence of the chemotherapeutic drug doxorubicin, we isolated FL/Doxo cells which are
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4094::98fe6a00ba8d6508c18214abde8fcf01
http://hdl.handle.net/11585/619773
Zobrazit plný text záznamu
5
Systematic analysis of GSK-3 signaling pathways in aging of cerebral tissue
Autor: Dariusz Rakus, Agnieszka Gizak, D. Drulis-Fajdasz, Jacek R. Wiśniewski, J A McCubrey
Publikováno v: Advances in biological regulation. 69
Glycogen synthase kinase-3 (GSK-3) is a constitutively active kinase, involved in regulation of multiple physiological processes. In brain, changes in GSK-3 signaling are related to neurodegenerative issues, including Alzheimer's disease. Due to the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e2c8f41e5cb7f9924cc3cde1087cbbc
https://pubmed.ncbi.nlm.nih.gov/29958836
Zobrazit plný text záznamu
6
Introduction of WT-TP53 into pancreatic cancer cells with mutant TP53 alters sensitivity of chemotherapeutic drugs, targeted therapeutics and nutraceuticals
Autor: S. L. Abrams, K. Lertpiriyapong, L. V. Yang, A. M. Martelli, L. Cocco, S. Ratti, M. Falasca, R. M. Murata, P. L. Rosalen, P. Lombardi, M. Libra, G. Montalto, M. Cervello, L. S. Steelman, J. A. McCubrey.
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, highly metastatic malignancy and accounts for 85% of pancreatic cancers. PDAC patients have poor prognosis with a five-year survival of only 5–10%. Mutations at the TP53 gene are readily det
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4094::5a84a3be8cae184498f98940ecc77b62
http://hdl.handle.net/11585/643928
Zobrazit plný text záznamu
7
Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Module for Acute Myelogenous Leukemia Therapy: From Bench to Bedside
Autor: Wl Blalock, J A McCubrey, Camilla Evangelisti, Lucia Manzoli, Anna Maria Billi, P. L. Tazzari, Francesca Chiarini, Alberto M. Martelli, Lucio Cocco
Publikováno v: ResearcherID
The phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B, PKB)/mammalian Target Of Rapamycin (mTOR) signaling pathway plays a critical role in many cellular functions which are elicited by extracellular stimuli. However, constitutively active P
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60cddaa65ccae03eacf5320c7c9e50f4
https://doi.org/10.2174/092986707781368423
Zobrazit plný text záznamu
8
Elitek™–rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002
Autor: Michael R. Bishop, John P. Leonard, Jeha Sc, J A McCubrey, Stewart Goldman, Richard A. Larson, Mitchell S. Cairo, Pearce Te, Ching-Hon Pui, Carl Shanholtz, Patrick M. Navolanic
Publikováno v: Leukemia. 17:499-514
Renal precipitation of uric acid associated with tumor lysis syndrome (TLS) is a major complication in the management of leukemia, lymphoma, and other drug-sensitive cancers. Management of hyperuricema has historically consisted of administration of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21da0917d795edbe12385ec3c467c9a4
https://doi.org/10.1038/sj.leu.2402847
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje